Drug Profile

AKO 004

Alternative Names: AKO-004

Latest Information Update: 08 Mar 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Akome Biotech
Developer Akome Biotech; Complutense University Madrid
Class Antiparkinsonians; Dimethylamines; Drug withdrawal therapies; Indoles; Neuropsychotherapeutics; Organophosphorus compounds; Small molecules; Tryptamines; Vascular disorder therapies
Mechanism of Action Apoptosis stimulants; Serotonin 5-HT2 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Mar 2022 Akome Biotech and Universidad Complutense de Madrid agree to co-develop psychedelic compounds for the treatment of Alzheimer's disease, Parkinson's disease, major depressive disorder and ischaemic stroke
04 Mar 2022 Preclinical trials in Parkinson's disease in Spain, Canada
26 Jul 2021 Akome Biotech files for patent protection with the USPTO for AKO 004 in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com